235 related articles for article (PubMed ID: 35511629)
1. [The research progress of PD-1/L1 inhibitors application in the treatment of head and neck squamous cell carcinoma].
Song P; Yan X; Jiang Y; Ye Y; Wang J; Han P
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Apr; 36(4):315-320. PubMed ID: 35511629
[No Abstract] [Full Text] [Related]
2. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
3. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant PD-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma.
Huang S; Xiong C; Tan K
Am J Otolaryngol; 2023; 44(6):103985. PubMed ID: 37442083
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.
Mo DC; Huang JF; Luo PH; Chen L; Zou B; Wang HL
Eur Arch Otorhinolaryngol; 2023 Jan; 280(1):1-9. PubMed ID: 35907001
[TBL] [Abstract][Full Text] [Related]
7. Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.
Park JC; Krishnakumar HN; Saladi SV
Curr Oncol; 2022 Jun; 29(6):4185-4198. PubMed ID: 35735443
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.
Oualla K; Castelo Branco L; Nouiyakh L; Amaadour L; Benbrahim Z; Arifi S; Mellas N
Cancer Control; 2021; 28():10732748211004878. PubMed ID: 33827280
[TBL] [Abstract][Full Text] [Related]
9. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
Evrard D; Hourseau M; Couvelard A; Paradis V; Gauthier H; Raymond E; Halimi C; Barry B; Faivre S
Oncoimmunology; 2020 Nov; 9(1):1844403. PubMed ID: 33299655
[TBL] [Abstract][Full Text] [Related]
11. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.
Gao A; Pan X; Yang X; Lin Z
Invest New Drugs; 2021 Aug; 39(4):1132-1138. PubMed ID: 33594603
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
[TBL] [Abstract][Full Text] [Related]
16. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
Vathiotis IA; Johnson JM; Argiris A
Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
[TBL] [Abstract][Full Text] [Related]
17. Role of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yin G; Guo W; Duan H; Huang Z
Clin Otolaryngol; 2021 Sep; 46(5):1013-1020. PubMed ID: 33765363
[TBL] [Abstract][Full Text] [Related]
18. PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma.
Su NW; Dai SH; Hsu K; Chang KM; Ko CC; Kao CW; Chang YF; Chen CG
Cancer Immunol Immunother; 2024 Jan; 73(1):3. PubMed ID: 38175307
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy had a higher ORR than mono-immunotherapy in untreated HNSCC: Meta-analysis.
Chen S; Yang Y; Wang R; Fang J
Oral Oncol; 2023 Oct; 145():106479. PubMed ID: 37478574
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives.
Ran X; Yang K
Drug Des Devel Ther; 2017; 11():2007-2014. PubMed ID: 28721019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]